Kornimate/medical-research-clean huggingface dataset:
platelet reactivity in sepsis syndrome (press)

Conditions: Sepsis Syndrome

Summary: activation of blood platelets is a typical finding in patients with systemic inflammation and sepsis.they seem to mediate key pro-inflammatory mediator secretion, immune-cell activation while their adhesion to the endothelium enhances the pro-coagulatory activity of endothelial cells impairing microcirculation thus, may lead to multiple organ dysfunction. however, the exact effects of bacterial products on platelet function have not been found to be consistent and may vary according to the species, the timing of the study, and the pathogenesis of sepsis. data vary, including both increased and decreased platelet reactivity and aggregation among patients with sepsis compared to healthy controls. defining platelet's behaviour during sepsis is particularly important in view of recent findings revealing potential association between antiplatelet therapy and reduction in short term mortality, incidence of acute lung injury and intensive care unit admission in critically ill patients.this study aims to measure p2y12 mediated platelet reactivity, -using the point-of-care p2y12 verifynow assay, in platelet reactivity units (pru)- along different stages of sepsis, including bacteremia/uncomplicated infection, sepsis, severe sepsis and septic shock. subgroup follow up of patients going along different stages will also be performed. at the end of this study analysis of clinical and laboratory findings in correlation with platelet reactivity will be performed to assess platelet aggregation during sepsis.


Eligibility criteria:
inclusion criteria: * patients presenting 0-8 hours post admission with signs of one of the following i) uncomplicated infection/bacteremia ii) sepsis iii) severe sepsis iv) septic shock * 30 healthy subjects * signed informed consent exclusion criteria: * pregnancy * breastfeeding * inability to give informed consent * plts\ 741.000 ul * ht\ 52% * history of p2y12 or gpiib/iiiainhibitors the last 15 days prior assortment * patients with inherited (vonwillebrand factor deficiency, glanzmann thrombasthenia, bernard-sulier syndrome) or established acquired platelet disorders (hit) * patients undergoing hemodialysis * history of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months. * previous history of immunologic disease (neoplasm, autoimmune disorders, hiv) * subjects receiving daily treatment with immune-modulating regimens.

Keywords: sepsis platelet platelet reactivity p2y12
ondansetron versus domperidone for treating vomiting in acute gastroenteritis in children

Conditions: Vomiting in Infants and/or Children; Acute Gastroenteritis

Summary: most of the trials conducted comparing ondansetron and domperidone have been conducted among children aged below 5 or 6 years of age while no study from pakistan has compared efficacy of these antiemetic agents among children up to 12 years of age. the findings of present study will give valuable evidence about the effectiveness of these antiemetic agents to prevent vomiting among children suffering with acute gastroenteritis at a resource limited setting of south punjab, pakistan.

to compare the efficacy of ondansetron versus domperidone for treating vomiting in acute gastroenteritis in children at a resource limited emergency setting of south punjab, pakistan.

Eligibility criteria:
inclusion criteria: * children of both genders aged below 12 years of age having 3 or more non-bilious, non-bloody vomiting episodes within 24 hours and with suggestive signs and symptoms of acte gastroenteritis. exclusion criteria: * children who took any kinds of antiemetic in the last 6 hours of presentation of emergency department. * children having chronic liver disease, chronic kidney disease or congenital heart disease, neurological disorders, any kinds of malignancy, severe dehydration (requiring intravenous fluid replacement), severe acute malnutrition (weight-for-height below -3 standard deviation (sd) adopting who child growth protocols) or history known to allergy to antiemetics.
sodium chloride and protein-bound toxin removal in hemodiafiltration

Conditions: End-stage Renal Disease

Summary: an increase of the free fraction may allow a better removal of of protein-bound uremic toxins during dialysis. during predilution hemodiafiltration, the sodium chloride (nacl) concentration will be increased in the infusion fluid at a target nacl concentration and the effect on the removal of protein-bound toxins will be determined. comparisons will be made to standard hemodialysis and hemodiafiltration.

eight maintenance dialysis patients will be enrolled in a prospective, randomized, crossover trial. hd will be compared with online pre-dilution hdf and hdf at increased plasma ionic strength. the ionic strength will be increased using an infusion fluid with hypertonic \[na+\] by isovolumetric adding of a 5000 mmol/l nacl solution. blood and dialysate flowrates (250 and 575 ml/min, respectively), treatment time (240 min), and high-flux dialyser (surface area 2.1 sqm, purema h) will be always kept identical. anticoagulation with standard or fractionated heparin will be unchanged adopted from the patients' routinely used regimen. in both hdf modes, the infusion flow rate will be 125 ml/min. in hdf at increased plasma ionic strength, the infusate \[na+\] will be adjusted to approach 240 mmol/l in plasma entering the dialyser and the dialysate \[na+\] will be set at the technically feasible minimum of 130 mmol/l. blood samples will be drawn from the arterial and venous blood lines and, if applicable, from the blood tubing connecting the two dialyzers at 0, 15, 30, 60, 120, 180, and 240 min. samples at 240 min will be drawn after reducing the blood flow rate to 50 ml/min for 30 s and the dialysate flow turned off. a fraction of the spent dialysate will be continuously collected. removal of the free and total fraction of para-cresyl sulfate and indoxyl sulfate will be determined by reduction ratios, dialytic clearances and mass in dialysate hemocompatibility will be assessed by wbc and platelet counts, free hb, ldh, c5a and tat. \[na+\] will be monitored in both arterial (i.e. before nacl infusion) and venous blood of the extracorporeal system.

Eligibility criteria:
inclusion criteria: * end-stage renal disease * maintenance hemodialysis or hemodiafiltration for more than 3 months * stable clinical condition * \> 18 years exclusion criteria: * life expectancy less than 1 year * pregnancy * active infectious disease

Keywords: maintenance hemodialysis or hemodiafiltration >18 years stable condition
fatigue intervention co-design study in teenagers and young adults with cancer

Conditions: Fatigue

Summary: fatigue is one of the most common and distressing symptoms in teenage and young adult cancer patients. despite this, there has been virtually no research evaluating treatment for cancer-related fatigue in this young patient group. the investigators are undertaking a small qualitative study to co-design a fatigue intervention, that will then be evaluated in future research to assess its effectiveness.

this small qualitative study will involve 7-10 patients who are within one year of completing cancer treatment, as well as some parents. participants will be recruited from one centre, the cambridge teenage and young adult cancer principal treatment centre. the three phases will involve a) participants being interviewed individually and attending a focus group, b) patients receiving the prototype co-designed intervention, and c) participants being interviewed after the intervention to provide feedback to allow further refinement of the intervention. the intervention will be delivered by an allied health professional in the setting that participants have chosen. it is likely to involve, at a minimum, education about fatigue and support with increasing activity. it will not include administration of any medication.

Eligibility criteria:
inclusion criteria: patients: * aged 16-27 with a diagnosis of cancer * currently or previously known to the cambridge teenage and young adult cancer service * primary cancer treatment completed within one year of recruitment or on maintenance treatment for leukaemia. * a screening score of ≥5 in a 10-item numerical rating scale of fatigue severity over the last month * able to give informed consent parents: * the parent of a patient participant or a patient who would be eligible to participate * the patient consents to the parent being approached about the study * the parent is able to give informed consent exclusion criteria: * current participation in another clinical trial
study of polymorphisms of raas and mmps in acute heart failure

Conditions: Acute Heart Failure

Summary: this study aim to investigate the: * association of raas polymorphisms and ahf * association of mmp 3 and 12 polymorphisms and ahf

heart failure can be defined as a complex clinical syndrome that results from any structural or functional disorder of the heart, with impairment of ability to fill the ventricles or eject blood. the main event of the ic is dyspnea and fatigue, which limit exercise tolerance and induces water retention. the renin angiotensin aldosterone system governs the salt and water homeostasis in the body. renin is a proteolytic enzyme secreted by the juxtaglomerular apparatus of the kidney (area near the glomeruli). renin has no direct action on the organism, but that is part of the renin-angiotensin system or the renin-angiotensin-aldosterone system is known. to date, few published studies have examined the association between the polymorphism agt m235t \* and cardiac dysfunction; and available results are contradictory. what is not known yet is the ratio of this polymorphism with the prognosis of heart failure.

Eligibility criteria:
inclusion criteria: * aged more than 18 year old. * acute non traumatic dyspnea . exclusion criteria: * ecg diagnostic for acute myocardial infarction or ischemic chest pain within the prior 24 hours * a history of a heart transplant, pericardial effusion, chest wall deformity suspected of causing dyspnea * coma, shock,mv,vasopressor drugs * arrhythmia serious and sustained, * pace maker * severe mitral valve disease,

Keywords: acute heart failure raas mmp3 mmp12 polymorphysm
study of endoscopic barrett's esophagus diagnosis

Conditions: Barrett's Esophagus; GERD

Summary: barrett's esophagus (be) is a condition that often occurs in patients who have had gerd for a long time. the researchers are interested in be because it can sometimes become a cancer in the esophagus. the way that we currently diagnose be is by performing an upper endoscopy and looking for a change in the color of the esophagus. this color change may represent be. if the doctor sees this, he/she may take biopsies of this area. studies have shown that making the diagnosis of be can be hard to make. one of the reasons why this may be is because doctors may interpret what they see differently during the procedure. in other words, they may see an esophagus that appears normal in color or abnormal in color. the purpose of this study is to compare two doctors' impressions of the appearance of the esophagus during a single endoscopy procedure.


Eligibility criteria:
inclusion criteria: * history of (h/o) gerd * upper gi symptoms such as acid taste in mouth, dysphagia, dyspepsia * screening or surveillance exam for be exclusion criteria: * unable to consent * history of esophageal varices

Keywords: barrett's esophagus upper endoscopy esophageal biopsies accuracy interobserver agreement
roll for intervention - tbi group treatment

Conditions: Communication Disorder, Social

Summary: communication group intervention for individuals with traumatic brain injury based on insight protocol (keegan et al, 2020) with roll playing game focus

individuals with tbi recruited to participate in a study about applying insight protocol to a virtual roll playing game environment. the game 'monsters of the week' will be used to administer the cognitive-communication ingredients outlined by insight (keegan et al 2020) and progress towards social communication goals will be documented throughout the course of participating in the roll playing campaign (7-8 weeks - meeting 2 hours each week). the individuals without neurological disorders will follow the same protocol.

Eligibility criteria:
inclusion criteria: * moderate to severe tbi more than 1 year ago exclusion criteria: * other neurological diagnoses prior to tbi
hip scope fascia-iliaca (fi) block study

Conditions: Hip Dysplasia; Femoroacetabular Impingement; Acetabular Labrum Tear

Summary: patients undergoing a hip scope procedure will be recruited for this study. they will be randomized to either receive a nerve block or no nerve block (pain medicine only). pain levels and clinical outcomes will be assessed through 3 months post-operatively.


Eligibility criteria:
inclusion criteria: * scheduled for outpatient hip arthroscopy * american society of anesthesiologists (asa) 1-3 exclusion criteria: * prior surgery on ipsilateral hip * asa 4-6 * chronic narcotic usage over 6 months or more than the equivalent of 20mg of morphine per day * current or prior placement of a spinal cord stimulator or intrathecal pump for pain control purposes * allergy to amide local anesthetics * contraindication to regional anesthesia * bmi \> 40 * females who are pregnant or plan to get pregnant during the course of the study

Keywords: hip arthroscopy
diagnostic performance of exercise stress tests for the detection of epicardial and microvascular coronary artery disease

Conditions: Coronary Artery Disease

Summary: prospective, single-arm, multicenter study of patients with an intermediate pre-test probability of cad and positive exercise stress tests referred for invasive angiography. patients underwent an invasive diagnostic procedure (idp) with measurement of fractional flow reserve (ffr) and index of microvascular resistance (imr) in at least one coronary vessel. the objective was to determine the false discovery rate (fdr) of cardiac exercise stress tests with both ffr and imr as references.

the redefining the diagnostic performance of non-invasive tests for the detection of coronary artery disease: uz clear is an investigator-initiated, single-arm, multicenter, prospective study of patients presenting with chest pain with an intermediate probability of cad. the intermediate pre-test probability of cad was defined based on the european society of cardiology guidelines as a score between 15% and 85% based on age, sex, and the nature of symptoms. all patients had a positive exercise stress test and were referred for an invasive evaluation. patients underwent a study protocol with an invasive diagnostic procedure (idp) consisting of measurements of ffr and imr in at least one coronary vessel. exclusion criteria are acute coronary syndromes, known coronary artery disease, previous myocardial infarction, previous revascularization, and abnormal baseline electrocardiogram (ecg). all data were centrally collected and analyzed by the core laboratory. the primary objective was to determine the false discovery rate of exercise stress tests using an interventional diagnostic procedure (idp) with indexes of epicardial (ffr) and microvascular resistance (imr) as clinical references. the secondary objective was to assess the impact of an idp accounting for the presence of cmd on the accuracy of exercise stress tests.

Eligibility criteria:
inclusion criteria: - 1. stable angina-like chest pain (typical or atypical) with intermediate (15-85%) pre-test probability of coronary artery disease using the esc criteria. 2. positive non-invasive exercise test, or inconclusive stress with additional positive imaging. exclusion criteria: 1. age \ 80-year old 2. acute coronary syndromes. 3. known coronary artery disease 4. inability to perform exercise tests. 5. previous myocardial infarction. 6. previous cabg/pci 7. left ventricular dysfunction ef \<35% or nyha class iii-iv 8. uncontrolled or recurrent ventricular tachycardia 9. atrial fibrillation 10. severe renal dysfunction, defined as an egfr \<30 ml/min/1.73m2 11. contra-indication to adenosine (e.g. asthma bronchial, severe copd) 12. active cancer 13. recent stroke 14. cardiomyopathy (dilated, hypertrophic, amyloidosis, arrhythmogenic right ventricular dysplasia) 15. left bundle branch block or baseline st-segment depression \>1mm. 16. congenital heart disease 17. more than moderate valve disease
interstim® amplitude study

Conditions: Urinary Urge Incontinence

Summary: this feasibility study will explore the effects of three different interstim amplitude settings on overactive bladder symptoms (oab).

this is a prospective, randomized, multicenter, single-blinded study to explore the efficacy and quality of life (qol) of 3 different amplitude settings.

Eligibility criteria:
inclusion criteria: 1. primary diagnosis of urinary urge incontinence (uui) as demonstrated on a 3-day baseline voiding diary demonstrating at least 3 uui episodes 2. female subjects 18 years of age or older 3. candidate for interstim lead placement 4. willing and able to accurately complete voiding diaries, questionnaires, attend visits, and comply with the study protocol (which includes maintenance of interstim ii programming settings over the course of the study) 5. willing and able to provide signed and dated informed consent 6. willing to maintain current regimen (dosage and frequency) of any overactive bladder (oab) medication exclusion criteria: 1. have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury 2. history of diabetes unless the diabetes is well-controlled through diet and/or medications 3. symptomatic urinary tract infection (uti) 4. have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 5. treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 6. implanted with a neurostimulator, pacemaker, or defibrillator 7. have knowledge of planned mris, diathermy, microwave exposure, high output ultrasonic exposure, or radio frequency (rf) energy exposure not included within the scanning conditions provided with the mri guidelines for interstim therapy 8. women who are pregnant or planning to become pregnant 9. characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements. 10. currently enrolled or planning to enroll in a potentially confounding clinical study during the course of the study (co-enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the medtronic study manager (or designee).

Keywords: urinary incontinence
clinical study on raman spectra of blood, saliva and urine in patients with cancer treated by modern therapy

Conditions: Lung Cancer; Liver Cancer; Stomach Cancer; Breast Cancer

Summary: blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of raman spectral.

blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of raman spectral

Eligibility criteria:
inclusion criteria: * 18-80 years old; * the patient whose tumor (tissue or cell) was first diagnosed by pathology; * plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional chinese medicine treatment and biological immunotherapy; * have relevant indications for treatment and have no contraindications; exclusion criteria: * severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases, etc.); * other circumstances considered inappropriate by the researcher to participate in the study;
the association between religious origin and age, and vitamin b12 and folic acid plasma levels in non jewish population in western galilee

Conditions: Vitamin B12 Deficiency; Folic Acid Deficiency

Summary: vitamin b12 deficiency is more widespread in the population than has been assumed so far. since a deficiency in this vitamin can lead to irreversible neurological damage, early diagnosis is essential. vitamin b12 is synthesized exclusively in micro-organisms, and in humans it is an essential component in methyl group transfer and cell division. the vitamin is crucially involved in the proliferation, maturation, and regeneration of neural cells. in combination with folic acid, as an enzymatic essential cofactor in the metabolism of homocysteine, vitamin b12 maintains low homocysteine levels. the aim of the present study is to investigate the relationship between religious origin and age, and vitamin b12 and folic acid plasma levels in non jewish population in western galilee. the investigators assumption is that the results of the study will contribute to early detection and treatment of vitamin b12 and folic acid deficiencies in order to prevent long term complications.


Eligibility criteria:
inclusion criteria: * age:18 and older * able to understand and to sign informed consent exclusion criteria: * gastrointistinal diseases * malignancy * psychiatric disorders * pregnancy * treatment with vit b12 or folic acid
a clinical study to evaluate the safety, tolerability, and efficacy of qlc1101 in combination with other therapies in the treatment of patients with advanced solid tumors harboring a kras g12d mutation

Conditions: Solid Tumor

Summary: a phase ib/ii clinical study to evaluate the safety, tolerability, and efficacy of qlc1101 in combination with other therapies in the treatment of patients with advanced solid tumors harboring a kras g12d mutation. the study includes phase ib (combination therapy with dose escalation stage) and phase ii (expansion stage). the study will includes a total of 4 cohorts: phase ib will enroll subjects in 4 cohorts (cohorts 1-4). subjects will be allocated to appropriate cohorts by the investigator according to specific indications and treated with the corresponding combination regimen for safety and tolerability assessment. the bayesian optimal interval (boin) design will be used for dose escalation and mtd determination. in phase ii, according to the results of the phase ib and smc decision, 1-2 appropriate dose groups will be selected. in the dose group(s), the sample size (including subjects in the dose escalation stage) will be increased to 20 for each indication according to the cohort for expansion to further evaluate the efficacy of qlc1101 combination therapy in the treatment of subjects with advanced solid tumors harboring kras g12d mutations


Eligibility criteria:
inclusion criteria: * subjects confirmed advanced (metastatic or unresectable) solid tumors with kras g12d mutations. * subjects who have failed or are unable to tolerate standard therapy, have no standard therapy, or refuse to receive standard therapy * the investigator confirms that the subject has at least one measurable lesion recorded by ct and/or mri according to recist v1.1 * ecog ps score: 0 or 1 exclusion criteria: * subjects who have been previously treated with inhibitors for kras g12d mutations * subjects with known immediate or delayed hypersensitivity or idiosyncratic reaction to the components of the drug products used in the study * subjects with known or symptomatic active central nervous system (cns) metastases or carcinomatous meningitis at screening